Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI - Get Free Report) saw unusually large options trading on Wednesday. Stock investors acquired 5,247 call options on the stock. This is an increase of 964% compared to the average volume of 493 call options.
Maravai LifeSciences Trading Down 5.4 %
Shares of Maravai LifeSciences stock traded down $0.13 on Friday, hitting $2.27. 12,718,611 shares of the company traded hands, compared to its average volume of 2,261,867. Maravai LifeSciences has a 52 week low of $2.07 and a 52 week high of $11.56. The company has a market cap of $573.24 million, a PE ratio of -1.38 and a beta of -0.08. The stock's 50 day moving average price is $3.96 and its 200-day moving average price is $5.80. The company has a current ratio of 10.74, a quick ratio of 9.94 and a debt-to-equity ratio of 0.89.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on MRVI shares. Baird R W downgraded Maravai LifeSciences from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 26th. Robert W. Baird lowered shares of Maravai LifeSciences from an "outperform" rating to a "neutral" rating and lowered their target price for the stock from $9.00 to $3.00 in a report on Wednesday, February 26th. UBS Group cut their price target on shares of Maravai LifeSciences from $8.00 to $2.50 and set a "neutral" rating on the stock in a report on Friday. Bank of America dropped their target price on Maravai LifeSciences from $9.00 to $8.00 and set a "buy" rating for the company in a research report on Monday, March 3rd. Finally, Guggenheim initiated coverage on Maravai LifeSciences in a report on Thursday, December 19th. They issued a "neutral" rating on the stock. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and a consensus price target of $8.22.
Read Our Latest Report on MRVI
Insiders Place Their Bets
In other news, General Counsel Kurt Oreshack sold 25,000 shares of Maravai LifeSciences stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $5.03, for a total value of $125,750.00. Following the completion of the transaction, the general counsel now owns 167,618 shares in the company, valued at approximately $843,118.54. The trade was a 12.98 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.63% of the stock is currently owned by insiders.
Institutional Investors Weigh In On Maravai LifeSciences
A number of institutional investors and hedge funds have recently bought and sold shares of the company. JPMorgan Chase & Co. increased its stake in shares of Maravai LifeSciences by 1,172.4% during the third quarter. JPMorgan Chase & Co. now owns 4,050,245 shares of the company's stock valued at $33,658,000 after buying an additional 3,731,924 shares during the period. Barclays PLC grew its holdings in Maravai LifeSciences by 349.2% during the 3rd quarter. Barclays PLC now owns 184,189 shares of the company's stock worth $1,531,000 after acquiring an additional 143,184 shares in the last quarter. Systematic Financial Management LP increased its position in Maravai LifeSciences by 14.7% during the 3rd quarter. Systematic Financial Management LP now owns 1,612,161 shares of the company's stock valued at $13,397,000 after purchasing an additional 206,499 shares during the period. Empowered Funds LLC bought a new stake in shares of Maravai LifeSciences in the 4th quarter valued at about $155,000. Finally, Bleakley Financial Group LLC lifted its position in shares of Maravai LifeSciences by 30.1% in the 4th quarter. Bleakley Financial Group LLC now owns 41,691 shares of the company's stock worth $227,000 after purchasing an additional 9,657 shares during the period. 50.25% of the stock is owned by institutional investors.
Maravai LifeSciences Company Profile
(
Get Free Report)
Maravai LifeSciences Holdings, Inc, a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species.
Featured Articles
Before you consider Maravai LifeSciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Maravai LifeSciences wasn't on the list.
While Maravai LifeSciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
